Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15946473 | 0.95 | GPR35 (0.39) | HPGDMEN1KMT2ASIRT3SMN1; SMN2 | |
| SCHEMBL14821502 | 0.91 | TAAR1 (0.40) | HPGDMEN1KMT2ASIRT3SMN1; SMN2 | |
| SCHEMBL14821149 | 0.85 | GPR35 (0.37) | KMT2ASMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL14821139 | 0.82 | TAAR1 (0.40) | HPGDMEN1KMT2ASIRT3SMN1; SMN2 | |
| SCHEMBL15948351 | 0.82 | TAAR1 (0.40) | HPGDMEN1KMT2ASIRT3SMN1; SMN2 | |
| SCHEMBL14821007 | 0.82 | HPGD (0.44) | HPGDMEN1KMT2ASIRT3SMN1; SMN2 | |
| SCHEMBL14821477 | 0.81 | PPARA (0.46) | HPGDMEN1KMT2ASIRT3SMN1; SMN2 | |
| SCHEMBL15946472 | 0.81 | HTT (0.36) | HPGDSMN1; SMN2MAPTALDH1A1HTT | |
| SCHEMBL15948337 | 0.81 | POLB (0.48) | HPGDSMN1; SMN2MAPTHTTLMNA | |
| SCHEMBL14821114 | 0.81 | PPARA (0.40) | HPGDMEN1KMT2ASIRT3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | IDH3A, IDH3B, IDH2 | HPGD 3189/4885MEN1 2893/4885KMT2A 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.